Elutia Q2 FY26 net loss narrows 20.4% to $7.6 million; net sales fall 11.7% to $2.4 million
Reuters2026/08/13 20:19- Elutia posted a GAAP net loss of $7.6 million for Q2 2026, narrowing from $9.6 million a year earlier.
- Net sales fell 11.65% to $2.4 million, reflecting a $0.7 million SimpliDerm revenue drop partly offset by a $0.4 million cardiovascular gain.
- GAAP gross margin rose 6.7 percentage points to 59.6%.
- Operating loss narrowed to $8 million from $8.4 million; total operating expenses eased to $9.4 million from $9.8 million.
- Secured up to $26 million without an equity offering; NXT-41 FDA decision expected 4Q 2026, NXT-41x expected 1H 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
US military strikes Iranian oil tanker, triggering geopolitical risks as Brent crude nears $97 mark
Following the US military's attack on Iranian oil tankers and Iran's announcement of new restricted navigation zones outside the Strait of Hormuz, market concerns over prolonged disruptions in key energy transport routes have intensified, leading to a sharp rise in international oil prices.
Geopolitical tensions overshadowing production cuts: OPEC+ maintains quotas unchanged, paper adjustments fail to resolve physical supply dilemmas
OPEC+ major oil producers, led by Saudi Arabia and Russia, held a monthly video conference last Sunday and decided to keep the crude oil production quota for October unchanged, continuing the previous tone of stable production following a series of symbolic production increases.
IX Biopharma seeks SGX-ST trading halt lift for shares in Singapore
No Public Money Behind El Salvador’s New Bitcoin, IMF Confirms
Crypto prices
More
